These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12086544)

  • 21. Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects.
    Ahmann PA; Theye FW; Berg R; Linquist AJ; Van Erem AJ; Campbell LR
    Pediatrics; 2001 Jan; 107(1):E10. PubMed ID: 11134474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.
    Swanson J; Wigal S; Greenhill L; Browne R; Waslick B; Lerner M; Williams L; Flynn D; Agler D; Crowley KL; Fineberg E; Regino R; Baren M; Cantwell D
    Psychopharmacol Bull; 1998; 34(1):55-60. PubMed ID: 9564199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autonomic correlates at rest and during evoked attention in children with attention-deficit/hyperactivity disorder and effects of methylphenidate.
    Negrao BL; Bipath P; van der Westhuizen D; Viljoen M
    Neuropsychobiology; 2011; 63(2):82-91. PubMed ID: 21178382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
    Wilens TE; Biederman J; Lerner M;
    J Clin Psychopharmacol; 2004 Feb; 24(1):36-41. PubMed ID: 14709945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of age and hypertension treatment-time on ambulatory blood pressure in hypertensive patients.
    Hermida RC; Ayala DE; Crespo JJ; Mojón A; Chayán L; Fontao MJ; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):176-91. PubMed ID: 23077974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.
    McGough JJ; Biederman J; Greenhill LL; McCracken JT; Spencer TJ; Posner K; Wigal S; Gornbein J; Tulloch S; Swanson JM
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):684-91. PubMed ID: 12921476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study.
    Trugman JM; Palmer RH; Ma Y
    Curr Med Res Opin; 2014 Apr; 30(4):589-97. PubMed ID: 24188161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Short EJ; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study of stimulant response in preschool children: insights from ROC analyses.
    Short EJ; Manos MJ; Findling RL; Schubel EA
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):251-9. PubMed ID: 15076257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results.
    Wigal SB; Wilens TE; Wolraich M; Lerner M
    Pediatrics; 2007 Jul; 120(1):e120-8. PubMed ID: 17548486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
    Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
    J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.
    Chen CY; Bussing R; Hartzema AG; Shuster JJ; Segal R; Winterstein AG
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):678-86. PubMed ID: 26597624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing stimulant medication for attention-deficit/hyperactivity disorder: an update.
    Wender EH
    Pediatr Rev; 2002 Jul; 23(7):234-6. PubMed ID: 12093933
    [No Abstract]   [Full Text] [Related]  

  • 38. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD.
    Witt KL; Shelby MD; Itchon-Ramos N; Faircloth M; Kissling GE; Chrisman AK; Ravi H; Murli H; Mattison DR; Kollins SH
    J Am Acad Child Adolesc Psychiatry; 2008 Dec; 47(12):1375-83. PubMed ID: 18978633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder.
    Negrao BL; Crafford D; Viljoen M
    Cardiovasc J Afr; 2009; 20(5):296-9. PubMed ID: 19907802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.
    Weisler RH; Biederman J; Spencer TJ; Wilens TE
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):35-43. PubMed ID: 16344839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.